Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
247 Leser
Artikel bewerten:
(1)

Otto Damsma Joins Bioforum as Vice President of Asia Pacific Operations

Bioforum Bolsters Leadership Team to Drive Expansion in Australia and Asia Pacific Region

NESS ZIONA, Israel, Dec. 14, 2020 /PRNewswire/ -- Bioforum, a global data-focused contract research organization (CRO), today announced the appointment of Otto Damsma as Vice President of Operations for Asia Pacific (APAC), where he will lead Bioforum's continued regional growth and expansion. Damsma has more than 30 years of experience in establishing and supervising biometrics and IT departments within pharmaceutical companies, contract research organizations (CROs) and academic settings.

"Otto adds valuable leadership to Bioforum during a period of strong growth," said Amir Malka, Bioforum's Co-Founder and President. "We're delighted that he is bringing his breadth of experience, insight and acumen to Bioforum to head up our operations in Australia and expansion across the APAC region."

"Over the years, Bioforum has established itself as a leader in medical writing, data management, statistical programming and biostatistics, delivering global operational excellence as a trusted partner to sponsors, particularly small-to-mid-size biotechs and innovative startups that are transforming drug development," Damsma added. "I am very excited to join the talented team at Bioforum as we continue to grow and leverage our unique value proposition to support our customers and industry in improving the health of people worldwide."

Damsma joins Bioforum from Australian specialist CRO Clinical Network Services (CNS), part of Novotech, the largest Asia-Pacific-based CRO, where he was Director of Clinical Programming and previously Director of Biometrics & IT from 2013-2019. Prior to CNS, Damsma was the Business Manager at The Centre for Integrated Preclinical Drug Development at the University of Queensland and a Business Development Officer, Queensland Clinical Trials Network (now Life Sciences Queensland). Earlier in his career, Damsma served as Director of IT/Information Management and Director of Biometrics at Astellas Pharma Europe, and Clinical Research Manager at Boehringer Ingelheim in Holland. He holds a certificate in post-doctoral information management and M.Sc. in Chemistry from the University of Amsterdam.

About Bioforum the Data Masters

Bioforum is a data-focused contract research organization (CRO), serving clients worldwide in optimizing the collection, standardization, and reporting of clinical research data. We strive to consistently improve and innovate data processes, enabling the most efficient data submissions for our clients across the life sciences industry worldwide. From our offices in Israel, the U.S., Australia, and South Africa, our multidisciplinary team provides in-depth expertise and delivers high-quality solutions, including medical writing, data management, clinical programming, biostatistics, and pharmacovigilance. To learn more about us and our services, visit bioforumgroup.com or find us on LinkedIn at linkedin.com/company/bioforum-ltd.

Bioforum Contact

Tali Rahinstein, VP Business Development
talir@bioforumgroup.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.